[Five patients with subacute sclerosing panencephalitis treated with intraventricular alpha-interferon and inosinpranobex].
We followed up 5 patients with subacute sclerosing panencephalitis (SSPE) for 14 to 81 months. They were treated with alpha-interferon (INF-alpha) and oral inosinpranobex (INP) in an early stage of Jabbour stage II and within 5 months after the onset. On admission, Ommaya reservoir was implanted for the intrathecal administration of INF-alpha. The dose was 1 x 10(5) U/m2 initially and daily increased to 1 x 10(6) U/m2. A total dose of 30 x 10(6) U/m3 was given to them over a 4-weeks to 6-weeks period. After discharge, a dose of 15 x 10(6) U/m2 in three patients was given weekly and a dose of 30 x 10(6) U/m2 in the other patients. In addition, all patients received oral INP. One patient showed mild progression and remained in early stage of Jabbour stage II. In the remaining 4 patients, the disease progressed to Jabbour stage III. Despite the small number of patients studied here, the results suggest that treatment with INF-alpha plus oral INP is ineffective in an early stage of SSPE.
Oshiro
Satoshi
S
Department of Pediatrics, Okinawa Seishi Ryogoen, Naha, Okinawa.
Minema
Hirotaka
H
Shiroma
Naohide
N
Hirayasu
Kyoumi
K
Nakada
Yukikatu
Y
D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage*; D002648:Child; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007276:Injections, Intraventricular; D007542:Inosine Pranobex / Q000008:administration & dosage*; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D011379:Prognosis; D013344:Subacute Sclerosing Panencephalitis / Q000188:drug therapy*
D000998:Antiviral Agents; D016898:Interferon-alpha; D007542:Inosine Pranobex